Related content

Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy

By Ko Soon Young   Choe Won Hyeok   Kwon So Young   Kim Jeong Han   Seo Jung Woong   Kim Kyun-Hwan   Lee Chang Hong  

Scandinavian Journal of Gastroenterology, Vol. 47, Iss. 11, 2012-11 ,pp. : 1362-1367

Informa Healthcare

Access to resources Recommend Favorite

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B

By Papadopoulos Vasileios   Protopapas Andreas   Tsianos Epameinondas   Mimidis Konstantinos  

Scandinavian Journal of Gastroenterology, Vol. 44, Iss. 8, 2009-08 ,pp. : 1021-1022

Informa Healthcare

Access to resources Recommend Favorite

Erratum to: Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

By Karino Yoshiyasu  

Hepatology International, Vol. 4, Iss. 4, 2010-12 ,pp. : 789-790

Springer Publishing Company

Access to resources Recommend Favorite

Erratum to: Add-On Adefovir Is Superior to a Switch to Entecavir as Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B

By Chung Goh  

Digestive Diseases and Sciences, Vol. 56, Iss. 8, 2011-08 ,pp. : 2509-2509

Springer Publishing Company

Access to resources Recommend Favorite

Therapie mit Entecavir bei chronischer Hepatitis B: BEHoLD-Studie (Benefits of Entecavir for Hepatitis B Liver Disease)

By Erhardt A.   Häussinger A.  

Der Internist, Vol. 48, Iss. 2, 2007-02 ,pp. : 208-210

Springer Publishing Company

Access to resources Recommend Favorite